For investors

A Specialty Pharmaceutical Company

Welcome to the 'For Investors' section of our website


Corporate Information


Neurentis plc is a UK-based specialty pharmaceutical company focused on the development and licensing of differentiated therapies for central nervous system disorders and rare neurodegenerative diseases. The company is building a diversified pipeline designed to address significant unmet medical needs through a disciplined "buy and build" strategy, acquiring and advancing clinically validated assets to defined value-creation milestones.

The company operates an asset-light model, engaging specialist contract research organisations for clinical development and collaborating with academic institutions and established pharmaceutical partners. This capital-efficient approach allows Neurentis to focus its resources on advancing its pipeline programmes while maintaining a lean organisational structure.

Depression treatment, Psychiatric disease, Novel drugs

The Investment Case for Neurentis


Neurentis offers investors the opportunity to gain exposure to a diversified neuroscience and rare disease pipeline through a single company. The key elements of the investment case include:

  • A late-stage lead programme (Quivara™) preparing for a Phase III clinical trial in treatment-resistant depression, supported by a strategic collaboration with a top-20 global pharmaceutical company.
  • Two orphan drug candidates targeting progressive supranuclear palsy, multiple system atrophy, and Perry syndrome, conditions with no currently approved treatments and the potential for orphan drug designation, which carries significant regulatory protections including extended periods of market exclusivity.
  • A capital-efficient, asset-light operating model designed to focus resources on clinical development rather than infrastructure.
  • An experienced leadership team with decades of combined experience in pharmaceutical development, licensing, and public capital markets.
  • A partnership-driven commercialisation strategy aligned with the pharmaceutical industry's established pattern of licensing and acquiring neuroscience assets from specialist development companies.

    • Company Summary

    Neurentis plc is a specialty pharmaceutical company focused on developing treatments for central nervous system disorders and rare neurodegenerative diseases. Our diversified pipeline includes five programmes targeting conditions with significant unmet medical needs, from treatment-resistant depression to orphan neurological disorders including Progressive Supranuclear Palsy, Multiple System Atrophy, and Perry Syndrome. We combine selective acquisition of late-stage assets with proprietary internal development, creating multiple pathways to commercial value for our shareholders.

    Management Team

    Our leadership brings decades of pharmaceutical industry experience from global leaders including GlaxoSmithKline, Bristol-Myers Squibb, and Novartis. The team has demonstrated expertise across drug development, regulatory affairs, commercial strategy, and the capital markets. The Board Directors are: Dimitri. F. Dimitriou, FRSM (Executive Chairman), Stephane Mery, DVM (CEO), Tony (Bijoy) Premi, MSc (Non Executive Director). Our board combines scientific insight with strategic guidance to navigate the complexities of bringing innovative therapies to market whilst building sustainable shareholder value.

    Business Model

    Neurentis operates a capital-efficient model that combines selective acquisition of promising late-stage assets with proprietary internal development. This "buy and build" strategy allows us to advance multiple programmes simultaneously whilst maintaining control over innovation and intellectual property. We focus on conditions with defined patient populations and established regulatory pathways, partnering with pharmaceutical leaders like Viatris for manufacturing expertise and commercialisation support. This approach reduces development risk and accelerates our route to market.

    Company Strategy

    Our strategy is to maximise value by targeting therapeutic areas with significant unmet needs and favourable regulatory environments. We focus on orphan drug candidates that qualify for market exclusivity and development incentives, whilst also advancing late-stage clinical assets in larger markets such as treatment-resistant depression. Strategic partnerships enhance our capabilities without diluting our intellectual property position. We maintain lean operations and concentrate resources on programmes with clear commercial potential and defined development pathways.

    Sector/Market Specialisation

    Neurentis specialises in neurological and neuropsychiatric conditions where existing therapies are inadequate or absent. Treatment-resistant depression affects a substantial proportion of patients who fail to respond to conventional antidepressants, representing a significant commercial opportunity. Our orphan disease programmes target rare progressive neurological disorders with no approved disease-modifying treatments, including Progressive Supranuclear Palsy and Multiple System Atrophy. These focused indications offer orphan drug designation benefits whilst addressing genuine patient needs.

    Route to Market

    We pursue a flexible commercialisation strategy tailored to each programme's characteristics and market dynamics. For orphan indications, we are evaluating both direct commercialisation in select territories and strategic partnerships with established pharmaceutical companies. Our collaboration with Viatris demonstrates this partnership model in action, providing manufacturing expertise and regulatory support. For larger market opportunities, we anticipate licensing arrangements that leverage partners' commercial infrastructure whilst preserving value for Neurentis shareholders through milestone payments and royalties.

    Pharma Market Potential

    The global pharmaceutical market continues its robust growth trajectory, driven by ageing populations, increased disease awareness, and evolving regulatory frameworks that support innovation. Specialty pharmaceuticals, particularly those targeting central nervous system disorders and rare diseases, represent areas of significant commercial opportunity. Orphan drug designations provide market exclusivity and regulatory advantages that enhance commercial returns. Our pipeline is positioned to capture value across multiple therapeutic segments with substantial unmet needs and favourable reimbursement environments.

    Product Portfolio & Pipeline

    Our portfolio comprises five distinct programmes across different development stages. Quivara addresses treatment-resistant depression through a novel transdermal delivery system. NRNT-042402 targets refractory epilepsy using AI-driven drug design. Neurobiomod is a natural formulation supporting nervous system health. NRNT-062501 is being developed for Progressive Supranuclear Palsy, whilst NRNT-072601 targets both Multiple System Atrophy and Perry Syndrome. This diversified pipeline provides multiple opportunities for value creation across varied timelines and risk profiles.

    Values

    Our fundamental values are of integrity alongside a desire to be honest and straightforward with one another. We are data-based and intellectually trustworthy while also recognising risks. We aspire to being leaders in our area of expertise, we have a clear vision of where we are going and focus our resources to achieve our objectives and strategies. We have a compelling desire to improve and to win in our sector We are a true partnership, ensuring we treat the company’s assets as our own while constantly having the company’s long term success in mind. We show respect for all, value differences and inspire achievement.

    Vision & Mission

    Our vision is to provide new medicines that improve the health of people suffering from serious diseases as well as the lives of their families and other carers. As a result of our vision and using our values, Neurentis will be successful in delivering true medical innovation around the world, together with its partners, and as a consequence be rewarded with leadership sales, profit and value creation, allowing our people, our shareholders and the various stakeholders to prosper. Innovation is the key to our business and we encourage outstanding Research & Development. We learn from both our successes and our failures; we work together with confidence and trust.

    Corporate Governance

    Neurentis is committed to maintaining standards of corporate governance appropriate for a company of its size and stage of development. As we continue to grow, we are implementing structures that ensure transparency, accountability, and strategic oversight in support of sustainable shareholder value creation. Our governance framework centres on Board independence and diversity, bringing together directors with complementary expertise and perspectives. We are establishing dedicated Audit, Remuneration, and Nomination Committees to provide focused oversight of financial reporting, executive compensation, and Board composition respectively. We adhere to strict ethical standards and maintain comprehensive compliance processes across all operations. Regular shareholder engagement through communications keeps our stakeholders informed of strategic progress. Our proactive risk management approach safeguards company assets and long-term viability, whilst our commitment to sustainability reflects responsible business practices that align with global standards.

    UN SDG principles

    Neurentis is dedicated to improving the lives of people who are suffering from neuropsychiatric disorders, and we believe that our work is closely aligned with several of the United Nations Sustainable Development Goals (SDGs). By developing innovative medicines to treat neuropsychiatric disorders, we are contributing to SDG 3, which aims to ensure healthy lives and promote well-being for all ages. In addition, our work has the potential to have a positive impact on SDG 10, which seeks to reduce inequalities within and among countries, by providing new treatment options for underserved patient populations. Finally, by promoting research and development in the field of neuroscience, we are also advancing SDG 9, which focuses on building resilient infrastructure, promoting inclusive and sustainable industrialization, and fostering innovation. Neurentis is proud to be part of a global community of companies and organizations that are working towards the achievement of the SDGs, and we remain committed to contributing to a more sustainable and equitable world through our work.

    Focused Innovation in Specialty Pharma

    A Compelling Opportunity in Neurological Therapeutics

    Neurentis is positioned at the intersection of significant patient need and commercial opportunity. Our pipeline targets conditions where effective treatments remain elusive, from rare progressive neurological diseases to treatment-resistant psychiatric disorders. Through strategic acquisitions, internal innovation, and partnerships with established pharmaceutical leaders, we are building a diversified portfolio designed for value creation. As we advance our programmes through clinical development and towards commercialisation, we invite investors to participate in our growth as a specialty pharmaceutical company dedicated to both patient impact and shareholder value.

    As with any investment in a development-stage pharmaceutical company, an investment in Neurentis carries risk. Prospective investors should read the risk factors set out in the company's Annual Report before making any investment decision.